BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16239425)

  • 1. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
    Delgado J; Thomson K; Russell N; Ewing J; Stewart W; Cook G; Devereux S; Lovell R; Chopra R; Marks DI; Mackinnon S; Milligan DW;
    Blood; 2006 Feb; 107(4):1724-30. PubMed ID: 16239425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
    Morris E; Thomson K; Craddock C; Mahendra P; Milligan D; Cook G; Smith GM; Parker A; Schey S; Chopra R; Hatton C; Tighe J; Hunter A; Peggs K; Linch D; Goldstone A; Mackinnon S
    Blood; 2004 Dec; 104(13):3865-71. PubMed ID: 15304395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
    Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
    Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD
    Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
    Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
    Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
    van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
    Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
    Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
    Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
    Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
    Kröger N; Shaw B; Iacobelli S; Zabelina T; Peggs K; Shimoni A; Nagler A; Binder T; Eiermann T; Madrigal A; Schwerdtfeger R; Kiehl M; Sayer HG; Beyer J; Bornhäuser M; Ayuk F; Zander AR; Marks DI;
    Br J Haematol; 2005 Jun; 129(5):631-43. PubMed ID: 15916686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
    Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
    D'Sa S; Peggs K; Pizzey A; Verfuerth S; Thuraisundaram D; Watts M; White H; Hale G; Waldmann H; Goldstone A; Mackinnon S; Yong K
    Br J Haematol; 2003 Oct; 123(2):309-22. PubMed ID: 14531914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
    Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.